


QF0301B

Cat. No.:	HY-101690
CAS No.:	149247-12-1
Molecular Formula:	C ₂₃ H ₂₈ N ₂ O ₂
Molecular Weight:	364.48
Target:	Adrenergic Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	QF0301B is an α 1 adrenergic receptor antagonist and a low α 2 adrenoceptor, 5-HT _{2A} , and histamine H ₁ receptor blocker.
IC₅₀ & Target	IC ₅₀ : Adrenergic receptor ^[1]
In Vitro	In isolated rubbed rat aorta rings, QF0301B shows marked α 1-adrenoceptor blocking activity, with a pA ₂ value of 9.00±0.12. QF0301B reverses and competitively antagonizes the inhibitory action produced by clonidine in electrically stimulated rat vas deferens and inhibits the force and rate of contraction in rat isolated atria (pA ₂ =5.91±0.43), competitively antagonizes the contractile effect of 5-HT in rat aorta (pA ₂ =6.75±0.06) and in rat stomach fundus (pA ₂ =7.13±0.48) and the contractions induced by histamine in isolated guinea pig longitudinal ileal muscle (pA ₂ =7.40±0.40). QF0301B shows noncompetitive low action in 5-HT ₃ , muscarinic and nicotinic receptors, or as Ca ²⁺ antagonist ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	QF0301B (0.1-0.2 mg/kg iv) can cause a pronounced and prolonged fall in mean arterial blood pressure accompanied by bradycardia. QF0301B does not significantly modify the cardiovascular effects of either 5-hydroxytryptamine (serotonin, 5-HT, 75 mg/kg iv) or the selective α 2-adrenoceptor agonist B-HT 920 (0.2 mg/kg iv), but markedly inhibits the hypertensive effect of noradrenaline (5 mg/kg iv), a nonselective α -adrenergic receptor agonist ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration ^[1]	Rats: Normotensive rats are anaesthetized. When blood pressure and heart rate have stabilized (30 min after cannulation), vehicle (1 ml/kg), QF0301B, or prazosin solution (0.1-0.2 mg/kg) is injected intravenously via the femoral vein, and the effects on blood pressure and heart rate are observed ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
---	--

REFERENCES

[1]. Orallo F, et al. In vivo and in vitro pharmacological studies of a new hypotensive compound (QF0301B) in rat: Comparison with prazosin, a known α 1-adrenoceptor antagonist. *Vascul Pharmacol.* 2003 Feb;40(2):97-108.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA